A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Reproxalap (Primary)
- Indications Anterior uveitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 25 Oct 2017 According to an Aldeyra Therapeutics media release, data from this trial will presented at the American Uveitis Society Fall Meeting held in conjunction with the American Academy of Ophthalmology 2017 Annual Meeting.
- 17 May 2017 According to an Aldeyra Therapeutics media release, data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting.
- 18 May 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History